GLP-1 Exposure Around Conception Shows No Clear Increase in Pregnancy Risks
Women exposed to glucagon-like peptide-1 (GLP-1) receptor agonists around conception and in the earliest stages of pregnancy do not face a clearly detectable increase in adverse outcomes for themselves or their babies. That finding emerges from a systematic review and meta-analysis published in the journal Med on September 29, 2026, which evaluated data from 2,118,215 pregnancies across ten separate studies.
From the total number of pregnancies reviewed, the researchers found 8,325 instances where women had used a GLP-1 receptor agonist near the time of conception and within six months preceding a positive pregnancy test. When comparing those exposed pregnancies against unexposed cohorts, investigators found no clearly detectable increase in risks such as miscarriage, stillbirth, congenital anomalies, preterm birth, gestational diabetes, high blood pressure, or excessive maternal weight gain.
Data From 2 Million Pregnancies Analyzed by Researchers
The systematic review specifically examined studies looking at medication exposure before conception and during the initial phase of gestation, often before individuals realized they were pregnant. Because many pregnancies remain unplanned, the review’s authors noted that accidental exposure to GLP-1 receptor medicines is likely to happen frequently.
Asma Khalil, professor of obstetrics and maternal foetal medicine at City St George’s, University of London, who served as lead author, provided context regarding the results for patients. “The message for patients is that if you discover you were taking one of these medicines before you knew you were pregnant, you should not panic,” Khalil said, advising individuals to speak to their healthcare teams for personalized support.
Regulatory Guidance and Cautions on Medication Safety
Despite the reassuring data from the Med study, the authors emphasized that the results do not constitute definitive proof that GLP-1 receptor agonists are safe during pregnancy, signaling that further research is required. That stance aligns with existing official directives from health regulators.
Guidance published by the Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026 states that GLP-1 medications should not be taken during pregnancy or immediately prior to attempting conception. The agency based its position on a lack of sufficient safety data regarding potential harm to the unborn fetus, alongside animal studies that linked GLP-1 exposure to fetal harm. The MHRA advises patients to stop semaglutide at least two months, and tirzepatide at least one month, before pregnancy.
Clinical Perspectives on Early Pregnancy Exposure
The Pharmaceutical Journal was told by Ashifa Trivedi, clinical lead pharmacist in medicines and neonates at Evelina London Children’s Hospital, that this new meta-analysis provides useful perspectives as the number of prescriptions for women of reproductive age grows. Inadvertent early exposure is bound to become more common, Trivedi noted.
“However, it is important that these findings are interpreted carefully,” Trivedi told The Pharmaceutical Journal. “Finding no detectable increase in adverse pregnancy outcomes following exposure around conception is not the same as demonstrating that these medicines are safe to use during pregnancy. The evidence is based on observational studies and therefore there remain important gaps in our understanding, including the effects of individual GLP-1 receptor agonists and exposure at different stages of pregnancy. They do not currently change recommendations that GLP-1 receptor agonists should not be used during pregnancy and should be stopped before a planned pregnancy.”
Common Questions Regarding GLP-1 Medications and Pregnancy
What did the Med study specifically investigate regarding GLP-1 exposure?
Researchers conducted a systematic review and meta-analysis of ten studies examining pregnancy outcomes in women who were exposed to GLP-1 receptor agonists before conception or during the very early, unrecognized stages of pregnancy. The analysis encompassed 2,118,215 total pregnancies, including 8,325 exposed cases.
What specific risks were evaluated in the review?
The meta-analysis evaluated miscarriage, stillbirth, congenital anomalies, preterm birth, gestational diabetes, high blood pressure, and excessive maternal weight gain, finding no clearly detectable increase in any of these outcomes compared with unexposed pregnancies.
How far in advance must specific GLP-1 drugs be stopped according to UK regulators?
The Medicines and Healthcare products Regulatory Agency advises stopping semaglutide at least two months, and tirzepatide at least one month, before pregnancy due to animal studies indicating potential fetal harm and a lack of human safety data.
Related reading